Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$113.33 - $163.85 $2.89 Million - $4.18 Million
25,500 Added 85.86%
55,200 $8.72 Million
Q4 2023

Feb 13, 2024

SELL
$67.31 - $124.76 $141,351 - $261,996
-2,100 Reduced 6.6%
29,700 $2.86 Million
Q3 2023

Nov 13, 2023

BUY
$102.5 - $123.59 $3.04 Million - $3.67 Million
29,700 Added 1414.29%
31,800 $3.85 Million
Q2 2023

Aug 11, 2023

SELL
$106.4 - $157.19 $2.66 Million - $3.93 Million
-25,000 Reduced 92.25%
2,100 $240,000
Q1 2023

May 12, 2023

SELL
$117.53 - $155.99 $22.9 Million - $30.4 Million
-194,800 Reduced 87.79%
27,100 $3.74 Million
Q4 2022

Feb 10, 2023

BUY
$100.86 - $132.13 $5.3 Million - $6.94 Million
52,500 Added 30.99%
221,900 $28.8 Million
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $5.21 Million - $8.2 Million
68,800 Added 68.39%
169,400 $18.7 Million
Q2 2022

Aug 12, 2022

BUY
$62.69 - $88.44 $5.79 Million - $8.16 Million
92,300 Added 1112.05%
100,600 $7.54 Million
Q3 2020

Nov 13, 2020

SELL
$127.12 - $172.34 $1.49 Million - $2.02 Million
-11,700 Reduced 58.5%
8,300 $1.17 Million
Q2 2020

Aug 14, 2020

BUY
$93.0 - $171.7 $1.49 Million - $2.75 Million
16,000 Added 400.0%
20,000 $3.21 Million
Q3 2019

Nov 08, 2019

SELL
$72.81 - $156.91 $1.49 Million - $3.2 Million
-20,400 Reduced 83.61%
4,000 $301,000
Q2 2019

Aug 14, 2019

SELL
$112.21 - $151.95 $6.33 Million - $8.57 Million
-56,400 Reduced 69.8%
24,400 $3.71 Million
Q4 2018

Feb 13, 2019

BUY
$97.32 - $148.76 $3.93 Million - $6.01 Million
40,400 Added 100.0%
80,800 $8.82 Million
Q3 2018

Nov 13, 2018

BUY
$115.31 - $161.51 $4.66 Million - $6.53 Million
40,400 New
40,400 $6.53 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.9B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.